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There are several treatments available to newly diagnosed prostate cancer (PCA) patients.
Although surgery and radiotherapy (RT) with or without androgen deprivation therapy (ADT)
are widely adopted treatment options for localized PCA together with active surveillance
(AS), there is no consensus nor randomised trials on treatment selection, prospective qual-
ity of life (QOL), along with toxicity outcomes and according to treatment modality in the Ital-
ian population. The current study aimed to describe clinical-therapeutic features and QOL at
PCA diagnosis, according to different treatment patterns in a large prospective, Italian popu-
lation, enrolled in the Pros-IT CNR study.
Methods
The Pros-IT CNR is an on-going national, multicenter, observational, prospective study on
patients affected by PCA who have been referred by 97 Italian Urology, Radiation Oncology
and Medical Oncology facilities participating in the project. The possible relationships
between the treatment patterns reported in the 6 month follow-up case report form and
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patients’ features at diagnosis were evaluated using exploratory multiple correspondence
analysis (MCA) and other data analysis method.
Results
At diagnosis, surgery and AS patients were significantly younger, had fewer comorbidities,
lower PSA levels and Gleason Score (GS) values; they were also diagnosed at an earlier
stage of disease with respect to the RT or ADT patients who showed significantly worse
QoL scores at the time of diagnosis.
Conclusions
An analysis of the data collected at baseline and 6 months later uncovered substantial differ-
ences in ages, comorbidities, clinical and QOL features in the various treatment groups.
These findings do not fully reflect the current PCA treatment guidelines and suggest the
need for a multidisciplinary consensus guideline to ameliorate both the counselling and
treatments of PCA patients.
Introduction
Even if national and international guidelines consider both surgery and radiotherapy (RT) as
treatments of choice for localized Prostate Cancer (PCA) [1–5], no randomized trials com-
pared their efficacy in different risk groups, with the exception of Hamdy’s study which exam-
ined 10-year outcomes of localized PCA treatments [6]. Active surveillance (AS), with the
advantage of avoiding radical treatments side effects is also considered an option for patients
affected by low/very low risk PCA [7–8].
Patients choosing to be treated may ultimately decide for themselves which treatment to
undertake only after having received an adequate counselling and after having shared their
decision with doctors [9]. Indeed, they may be confused by differing opinions experiencing
the ‘lost patient syndrome’ that may get even worse if there is a lack of communication
between different members of a multidisciplinary team (MDT) [10], even if managing patients
with PCA in a MDT is considered desirable [11].
The study aims to assess the association of clinical and quality of life (QOL) characteristics
with different patterns of care in a sample of PCA patients in Italy.
Materials and methods
“Pros-IT CNR” study
The design of the Pros-IT CNR study has been described elsewhere [12–13]. Briefly, this on-
going national, multicenter, observational, prospective, study was designed to monitor QoL in
a sample of treatment-naïve Italian patients with PCA diagnosed between 2014 and 2015.
Ninety-seven centers (urology, radiation and medical oncology facilities) located in Italy,
enrolled 1705 consecutive patients: 949 in urology, 717 in radiation oncology and 39 in medi-
cal oncology departments. A baseline evaluation at the time PCA was diagnosed (and the
patient was enrolled), and, 6, 12, 24, 36, 48 and 60 months later were/are foreseen for protocol
[14]. Complete information about the chosen treatment was available at the 6 months follow
up for the vast majority of patients enrolled (1493 patients at 6 months follow up, 97% of
expected).
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Ethics
The study protocol was approved by the Ethics Committee of the clinical coordinating center
(Sant’Anna Hospital, Como, Italy; register number 45/2014) and by those of the other partici-
pating centers. The study was carried out in accordance with the principles of the declaration
of Helsinki. All the participants signed an informed consent form.
Study population
In the Pros-IT CNR study, 1705 patients were enrolled. For the present analysis 6-month fol-
low-up data were available for 1537 patients without distant metastasis (while 32 had distant
metastasis at diagnosis, 4 died and 132 were lost to follow-up) (Fig 1).
Data collection
Demographics/anamnestic data (weight, height, smoking status), comorbidities evaluated
using the Cumulative Illness Rating Scale (CIRS) [15], pharmacological treatments, initial
diagnosis, tumor stage and QOL scores were evaluated at the baseline (time of diagnosis).
Information on life status, treatments prescribed and QOL are/were collected during follow-
up evaluations. Characteristics of institution where the prostate cancer was diagnosed (pres-
ence of Urology unit, Radiation Oncology Unit, Medical Oncology Unit and/or Prostate Can-
cer Unit) as well as physician who enrolled the patient in the study (urologist,radiation
oncologist or medical oncologist) were also collected.
Outcome measures analyzed
Patients’ QOL was assessed at diagnosis and then during each follow-up evaluation using the
Italian version of the University of California Los Angeles-Prostate Cancer Index [16], which
measures health-related QOL in PCA by investigating six domains: urinary function and
bother (UF, UB), bowel function and bother (BF, BB), sexual function and bother (SF, SB).
Responses were scored from 0 to 100, and higher score mirror better QOL.
Fig 1. Patients enrolled in the Pros-IT CNR study from prostate cancer diagnosis to the 6 months follow-up.
https://doi.org/10.1371/journal.pone.0224151.g001
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Additionally, the Italian version of the Short-Form Health Survey (SF-12 Standard v1 scale)
[17] was administered. SF-12 includes physical/mental component subscales (PCS and MCS,
respectively) both ranging from 0 to 100, with higher scores indicating better self-perceived
health states.
Statistical analysis
Data were analyzed without imputation of missing values. Categorical variables were presented
as numbers and percentages. Continuous variables were reported as means and standard devi-
ations (SD) or medians and quartile 1 (Q1) and quartile 3 (Q3). Normal distributions for con-
tinuous variables were tested using the Shapiro-Wilk test.
The patients’ features at diagnosis, as well as the characteristics of institution where the
prostate cancer was diagnosed (presence of Urology, Radiation Oncology or Medical Oncol-
ogy Unit and/or Prostate Cancer Unit) were compared according to the different treatments
selected for PCA applying Fisher’s exact test or Chi-squared test for categorical variables; the
Wilcoxon rank-sum test was employed to analyze the continuous variables. Post-hoc analyses
with Bonferroni adjustment for multiple comparison were applied.
Exploratory multiple correspondence analysis (MCA) was performed to evaluate the rela-
tionships among patients ‘characteristics at diagnosis to identify specific profiles [18–19].
MCA permits viewing graphically the relationships among variables, by defining a map of
cross-tabulations where rows and columns are represented as profiles in multidimensional
space. In MCA, active variables were used to search for the factorial solution (inertia), and
included age, education, marital status, smoking status, family history of PCA, presence of dia-
betes, comorbidities, T stage, Gleason Score (GS), PSA level and characteristics of institution
where the prostate cancer was diagnosed (presence of Urology, Radiation Oncology, Medical
Oncology Unit, Prostate Cancer Unit). PCA treatments prescribed during the 6 months fol-
lowing diagnosis were considered as supplementary variables. A p-value of less than 0.05 for a
2-sided test was considered statistical significant. All the analyses were performed using SAS
9.4 software. Full data were presented at the Uro-Oncological Study Group Meeting during
the Italian Radiation Oncologist National Conference recently held in Rimini (27–29 Septem-
ber 2019).
Results
Treatment was stratified as follows: surgery alone (37.6%); surgery and RT (2.4%); surgery
plus RT plus Androgen Deprivation Therapy (ADT; 1.8%); surgery and ADT (3%); exclusive
RT or RT plus ADT (22% and 15%, respectively), ADT alone (7%), AS (6%) and brachytherapy
(BT) (1%) (Fig 2). Information on treatments carried out during the six-month period follow-
ing diagnosis was unavailable for 26 patients. The treatment groups included in these descrip-
tive analyses were: surgery alone, surgery combined with RT, surgery combined with RT and
ADT, exclusive RT, RT combined with ADT, AS and ADT alone; a total sample size of 1412
patients was considered for the present study.
Treatment features
Overall, 690 patients without distant metastasis at diagnosis underwent surgery for PCA. Of
these, 58.8% underwent a robot-assisted radical prostatectomy (RARP), 24.1% an open radical
prostatectomy (ORP), 15.7% a laparoscopic prostatectomy and 0.4% a palliative transurethral
resection of the prostate. Information on the surgical approach was unavailable for less than
1% of patients. Three hundred seventy-six patients (57.6%) underwent nerve-sparing surgery
and 328 (47.5%) lymphadenectomy.
Prostate cancer treatments in Italy (Pros-IT CNR)
PLOS ONE | https://doi.org/10.1371/journal.pone.0224151 November 1, 2019 4 / 14
RT with external beams was delivered to 634 patients of whom 75% underwent Image-
Guided Radiation Therapy (IGRT). A three-dimensional conformal radiotherapy (3D-CRT)
technique was used in 200 patients (33.2%), Intensity-Modulated Radiation Therapy (IMRT)
in 248 (41.2%), Volumetric Modulated Arc Therapy (VMAT) in 147 (24.4%) and Stereotactic
body radiotherapy (SBRT) in 7 (1.2%). The volume treated included prostate alone in 142
patients (24.7%), prostate plus seminal vesicles in 340 patients (59.2%) and prostate, seminal
vesicles and pelvic nodes in 92 (16%). Active Surveillance was adopted in 90 patients (5.9%),
while 413 received ADT: LH-RH agonist (215; 56.1%) was the most frequently prescribed
ADT. LH-RH antagonists were prescribed to 55 patients; peripheral antiandrogen drugs to 43
and total androgenic blockade to 70.
Correlations between patient’s characteristics and therapeutic features
Patients’ characteristics at diagnosis, stratified by treatments received until follow-up at 6
months are outlined in S1 Table. Patients undergoing surgery alone or combined with RT or
Fig 2. Prostate cancer treatments reported at the follow-up at 6 months.
https://doi.org/10.1371/journal.pone.0224151.g002
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with RT/ADT were the youngest, along with those candidates to AS, followed by patients on
RT and those on ADT (p<0.0001). The prevalence of diabetes at diagnosis was 28.4% among
patients on ADT alone, 22.8% among those on RT combined with ADT, 17.5% among those
on exclusive RT and was� 10% among those on surgery alone or AS (p<0.0001 across
groups). Higher percentages of patients undergoing ADT alone, RT combined with ADT or
exclusive RT had three or more moderate/severe comorbidities according to CIRS (22.2%,
19.7% and 18%, respectively), compared to patients on AS or surgery (14.6% and 10.7%,
respectively). They also reported taking a higher median number of drugs taken (2, 3 and 2),
compared to patients undergoing surgery alone or AS (1 and 1; p = 0.0013 and p<0.0001,
respectively). There were no significant differences in the groups in the obesity prevalence
rates.
The median PSA value at diagnosis was 6.5 ng/mL (Q1 = 5, Q3 = 9.1) and 6.2 ng/mL
(Q1 = 4.8, Q3 = 7.7) in the surgery alone and AS groups, respectively. These values were signif-
icantly lower than those in the RT alone (7.0 ng/mL, Q1 = 5.2, Q3 = 10) and ADT (10.2 ng/
mL, Q1 = 7, Q3 = 21) groups. Ninety-three percent of patients in AS, 50.8% in surgery alone,
45.9% in RT alone, and 17.8% in ADT alone groups had a GS� 6 at diagnosis (p<0.0001).
Considering the physician who enrolled each patient, 94.8% of patients in the surgery alone
group were enrolled by urologists, 4.8% by radiation oncologists and 0.4% by medical oncolo-
gists. Conversely, 89.9% of patients in the RT group were enrolled by radiation oncologists,
8.4% by urologists and 1.7% by medical oncologists. Patients in the RT combined with ADT
group were enrolled by urologists in 47.3% of cases, by radiation oncologists in 44.6% of cases
and by medical oncologists in 8.2% of cases.
As far as QOL at diagnosis was concerned, the patients in surgery alone or AS groups had
better UF, BF, SF, SF12 PCS scores than the others (p<0.05). As described in Porreca A et al.
[13], features at diagnosis associated with lower SF12 PCS scores (i.e. worst physical compo-
nent scores) were older age, obesity, the presence of three or more moderate/severe comorbid-
ities, having a Gleason score at diagnosis of�8, living in Southern regions of Italy and being
widowed or single. Patients’ characteristics at diagnosis associated with lower SF12 MCS scores
(i.e. worst mental component score) were younger age, the presence of three or more moder-
ate/severe comorbidities and having a T-score at diagnosis higher than T1. The main charac-
teristic associated with lower UCLA-PCI scores was older age; furthermore, lower sexual
function scores were associated with the presence of diabetes, three or more moderate/severe
comorbidities, a T-score at diagnosis higher than T1 or a Gleason score of>8.
MCA analysis showed that inertia was decomposed along two principal dimensions (Fig 3).
The first axis accounted for 53% of the inertia and the second for a further 15%, giving a cumu-
lative inertia of 68%. Ten modalities contributed to almost 60% of the variance of the axis 1
(dimension 1): on the right of the axis, the most important modalities were PSA� 20 ng/mL at
diagnosis, GS� 8, T3 or T4 staging, being 75–79 at diagnosis, having diabetes and having been
enrolled by a medical or a radiation oncologist or in an Institution with no presence of an Urol-
ogy Unit; to the left side, the most important modalities were T1 staging, GS� 6, and being
under 65 years at diagnosis. Axis 1 grouped together the diagnosis severity (GS, T staging) with
age and diabetes. Four modalities contributed to 60% of the variance of the axis 2 (dimension 2):
having 3 or more comorbidities at diagnosis, having being diagnosed in an Institution without
Radiation or Medical Oncology Unit were towards the top of the axis, while the main contribu-
tors towards the bottom was having been diagnosed in an Institution with a Prostate Cancer
Unit. Supplementary variables (in this case, the treatment strategy selected) did not contribute
to determining the solution, but they were projected onto the axis to facilitate interpretation of
the analytical solution. AS and surgery alone were close to one other on the third quadrant,
together with a GS� 6, T1 staging, having at most two comorbidities, no diabetes, being
Prostate cancer treatments in Italy (Pros-IT CNR)
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younger than 69 years at the time of diagnosis and having being diagnosed in an Institution
with an urology unit. RT was plotted on the fourth quadrant, together with the presence of a
Medical or a Radiation Oncology Unit. ADT alone and RT plus ADT were plotted on the first
quadrant, near to� 80 years at diagnosis, a GS� 8, T3/T4, PSA�20 ng/ml and having been
enrolled by a medical oncologist. Surgery combined with RT and ADT was plotted on the sec-
ond quadrant, far enough from the other factors, but near to the lack of a Prostate Cancer Unit
in the Institution that performed the initial diagnosis. We chose not to consider QOL-related
factors as active variables, because they were self-reported and their inclusion in the analysis did
not substantially increase the inertia explained by the first two dimensions (70% vs 68%).
Discussion
The Pros-IT CNR study is mainly devoted to analyze the impact of patients’ and treatments
related features on QOL, and future analyses will evaluate changes in QOL following different
prostate cancer treatments. The present work aimed to analyze data collected, considering
patients’ clinical features at diagnosis, according to the treatment path. The study structure has
been conceived to take a picture of the “real world scenario” of Italian PCA patients treated in
different centers at time of diagnosis, allowing also to consider the clinical behavior of Italian
urologists and oncologists when choosing treatment for individual patient. The current study
uncovered that surgery alone closely followed by RT alone were the more frequently given
treatments, whereas ADT alone and AS were less frequently adopted. This finding is not unex-
pected as some authors have reported that surgical treatments have long been the most fre-
quently adopted strategy in Italy for PCA [20]. These findings are in line with a recent US
study, based on the Surveillance, Epidemiology and End Results (SEER) database, showing
that radical prostatectomy is the most commonly performed procedure (37% of patients) [21].
In the present series, surgery was found to be the preferred treatment for the youngest patients
without significant comorbidities. Indeed, patients undergoing surgery alone were younger
than those prescribed exclusive RT and ADT alone. Of the 690 patients who underwent radical
Fig 3. Multiple Correspondence Analysis of PCA patients’ characteristics at diagnosis.
https://doi.org/10.1371/journal.pone.0224151.g003
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prostatectomy, 58.8% underwent RARP, 24.1% ORP and 15.7% laparoscopic procedure. The
pattern may also be linked to some studies reporting that RARP can reduce post-operative
morbidity, hospital re-admissions and total admission time and can thus affect the QoL of
these patients [22–24]. Coughlin et al [24] recently conducted a phase III randomized trial ana-
lyzing functional and oncological postoperative outcomes up to 24 months after RARP or
ORP. There were no statistically significant differences in sexual functions, urinary distress or
clinical outcome, although the former showed a slightly better biochemical relapse free sur-
vival. The Authors concluded that both RARP and ORP yielded similar functional outcomes at
24 months, but they advised using caution in interpreting the oncological outcomes [25].
Pros-IT CNR data also support this conclusion [26].
In our data, 2.4% of patients underwent surgery followed by adjuvant RT, 1.8% surgery, RT
and ADT, 3% surgery and ADT, the latter in particular when the patient was characterized by
high risk features (T3 and GS >7).
Studies comparing cost-effectiveness and QOL in patients undergoing surgery vs RT vs
combined modality treatments have produced conflicting findings. While one report pub-
lished in 2012 favored RT plus ADT for high-risk PCA [27], another one published in 2013
supported the use of surgery for intermediate-to-high risk PCA [28]. When Dorth et al. con-
ducted a cost effectiveness analysis on intermediate-to-high risk PCA and compared RT plus
ADT vs surgery using a Markov model, their data showed that the former was characterized by
better results in terms of clinical outcome and quality-adjusted life expectancy [29–30]. An
increase in the fraction of high-risk patients treated with surgery has been reported also by the
aalysis of the SEER database for the years 2010–2015; this increase does not seem completely
justified by the current guidelines [31].
In Italy, an increase in the use of External Beam RT (EBRT) for curative treatment of PCA
has been documented in two subsequent patterns of practice studies run under the aegis of
Italian Association for Radiotherapy and Clinical Oncology (AIRO) [32–33]. In the present
study, patients treated with EBRT have been referred to radiation oncologist for the most by
urologists. Seventy-five percent underwent IGRT; 33.2% 3D-CRT technique, 41.2% IMRT,
24.4% VMAT, 1.2% SBRT. These results seem to confirm that the new technologies are
increasingly being used by Italian Radiation Oncology Centers. In comparison with previous
patterns of practice studies supported by AIRO, the percentage of PCA patients treated with
new RT technologies has increased considerably over recent years, confirming the conclusion
that IGRT can improve RT treatment accuracy [34] and may reduce severe acute and late uri-
nary/rectal side effects [35]. Furthermore, dose escalation, which IMRT/VMAT techniques
have greatly facilitated, has become increasingly commonplace in PCA patients in randomized
trials demonstrating improved disease control when increasing RT dose are applied [36–37].
More recent randomized trials have reported that moderately hypofractionated regimens are
equally effective and less disagreeable to patients compared to standard regimens since they
reduce total treatment time. These finding seem to support the use of more sophisticated RT
technologies (IMRT/VMAT) and IGRT techniques [38–40]. Also, in Italy, an increased use of
moderately hypofractionated, IGRT treatments has been observed in recent years (Table 1).
Finally, although extreme hypofractionated SBRT has been attracting growing interest, con-
vincing but less robust evidence has not led to a larger use [40–41].
In the United States (US) a progressive decline in BT was registered between 2004 and 2014
[21]. BT is available in some centers. However, the number of patients participating in the
Pros-IT CNR study who were prescribed this therapy was very small (1%) and reflects its
scarce diffusion at this moment in Italy. A recently published article, based on data from a
large multicenter Italian database, has confirmed the safety and efficacy of prostate BT [42].
Despite the many advantages of BT (shorter duration, good results and cost effectiveness), the
Prostate cancer treatments in Italy (Pros-IT CNR)
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explanation for its limited diffusion may be found in the scarcity of adequately trained radia-
tion oncologists also due to a relatively long learning curve [43].
In the recent years, a concomitant increase in the choice not to give definitive treatment
was also noted [21]. In the US, very recent data on a population of 164.760 PCA patients from
SEER database show an increase from 8.1% to 15.8% in AS as initial management from 2010
through 2015; this management strategy was applied to 42.1% of low risk patients in 2015 [31].
In our study, AS was adopted in 6% of the cases: according to the main guidelines [1–5], a
lower than expected fraction of patients with early stage PCA has been addressed to AS and
BT. At the same time, it seems that an excess of advanced stage patients has firstly been surgi-
cally treated as well as an excess of radical treatments for low/very low risk patients has there-
fore been proposed.
Several limitations of our study should be acknowledged: participating centers were
involved on a voluntary basis and, therefore, a selection bias cannot be excluded; information
on factors that could also influence physicians’ or patients’ treatment choice, including Mag-
netic Resonance Imaging, objective assessment of preoperative voiding status, volume of the
prostate, patients’ access to health care services, and surgeon’s experience, were not available
in the Pros-IT CNR study.
Concluding, the Pros-IT CNR study can be considered a remarkable forum for Italian urol-
ogy and oncology specialists to analyze and discuss the latest trends and patterns of care for
PCA. Future studies will help to clarify the efficacy of treatment strategies in different risk
groups and the baseline criteria to be used to select the most appropriate treatment path for
each patient.
Supporting information
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Table 1. Evolution of techniques and doses 1985 through 2015, according to different subsequent multicentric databases.
Technique/Dose Patterns of practice I
(1985–98)[31]
1759 patients
Patterns of practice II
(1999–2003)[32]
3001 patients






2D, n (%) 1315 (75) 725 (24) - -
3D, n (%) 444 (25) 2269 (75) 1905 (83) 200 (33)
IMRT, n (%) - 7 (1) 395 (17) 248 (42)
VMAT, n (%) - Not evaluated 147 (24)
SBRT, n (%) - - 7 (1)
Dose Gy, n (%)
< 70 728 (42) 218 (7) 24 (1) 107 (20)
70–75 1021 (58) 2531 (84) 1255 (70) 234 (46)
� 76 - 252 (9) 729 (29) 174 (34)
IGRT - - 334 (15) 476 (75)
�data presented at Urological study group meeting during AIRO Conference 2019
§present paper
https://doi.org/10.1371/journal.pone.0224151.t001
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